News
European shares were unchanged on Friday, as losses in heavyweight healthcare shares were countered by an advance in oil and ...
The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...
StockStory.org on MSN16h
Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To KnowA number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.
14h
MedPage Today on MSNResearchers Detail Alarming Rise in GI Cancers Among Young PeopleIn addition to obesity, modifiable risk factors include a low-quality diet (such as high consumption of processed meats, ...
GlaxoSmithKline LLC (GSK) plans to lay off 150 Cambridge workers. The layoffs come months after GSK said it had planned to ...
GSK plc (NYSE:GSK) is one of the best cheap stocks under $50 to buy now. On July 15, BofA analyst Sachin Jain maintained a ...
Explore more
Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of GSK plc’s ...
GSK PLC closed 19.70% below its 52-week high of £16.79, which the company achieved on September 9th.
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...
Oncologic Drugs Advisory Committee has voted against two proposed combination regimens containing GSK’s Blenrep (belantamab ...
Despite the setback with the Oncologic Drugs Advisory Committee vote, GSK emphasizes the unmet need in multiple myeloma and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results